51250-39-6

Upstream product

• 100-01-6 4-nitro-aniline 

Downstream Products

• 115307-95-4 bis-aziridin-1-yl-phosphinic acid-(4-nitro-anilide) 
• 773008-68-7 methyl N-(4-nitrophenyl)phosphoramidic acid 
• 136145-01-2 2-(p-nitroanilino)-2-oxo-5,5-dimethyl-1,3,2-oxazaphosphorinane 
• 82720-47-6 N,N,N',N'-tetramethyl-N''-(4-nitrophenyl)phosphoric triamide 
• 78258-13-6 N-4-nitrophenyl-dimethyl phosphoramidic acid ester 
• 63542-12-1 diethyl(N-(4-nitrophenyl))phosphoramide 
• 714905-28-9 sodium N-(4-nitrophenyl)phosphorodiamidic acid 
• 64077-25-4 (4-nitro-phenyl)-(2-oxo-2λ⁵-[1,3,2]oxazaphosphinan-2-yl)-amine 
• 1366596-12-4 2-(4-nitrophenylamino)-4-methyl-1,3,2-diazaphospholan-2-one 
• 77055-79-9 N-(4-nitrophenyl)phosphoric triamide 
• 82720-28-3 C₂₃H₂₆N₅OP 
• 82720-32-9 [4-(Acridin-9-ylamino)-phenyl]-phosphoramidic acid dimethyl ester 
• 344311-22-4 (4-Amino-phenyl)-phosphoramidic acid diethyl ester 
• 344311-07-5 C₁₀H₁₉N₄OP 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of phosphoramide derivatives as urease inhibitors

The design, synthesis, and biological evaluation of phosphoramide derivatives as urease inhibitors to reduce the loss of ammonia has been carried out. Forty phosphorus derivatives were synthesized and their inhibitory activities evaluated against that of jack bean urease. In addition, in vivo assays have been carried out. All of the compounds were characterized by IR, 1H NMR, MS, and elemental microanalysis. In some cases, detailed molecular modeling studies were carried out, and these highlighted the interaction between the enzyme active center and the compounds and also the characteristics related to their activity as urease inhibitors. According to the IC50 values for in vitro inhibitory activity, 12 compounds showed values below 1 μM and 8 of them represent improvements of activity in comparison to the commercial urease inhibitor N-n-butylthiophosphorictriamide (NBPT) (100 nM) (AGROTAIN). On the basis of the activity results and the conclusions of the molecular modeling study, a structural model for new potential inhibitors has been defined.

Syntheses and spectroscopic investigation of some cyclophosphazanes: Analysis of pseudo-triplet splitting

Some new phosphoramidates, 1-3, and the corresponding cyclophosphazanes, 4-6, with formula Cl2P(p-NHC6H4CH3) 1, Cl2P(O)(p-NHC6H4NO2) 2, (CH 3)2NP

Anomeric-like Substituent Effects on the Chair-Chair Conformational Equilibrium of the 2-Oxo-1,3,2-oxazaphosphorinane Ring System

The chair-chair equilibria for a series of 5,5-dimethyl-2-oxo-(2-p-X-anilino)-1,3,2-oxazaphosphorinanes were determined by 1H NMR. The percentage of chair conformer with the p-X-anilino group axial is increased by the presence of electron withdrawing X, while the opposite is true for electron-donor para X.Reasonably good linear plots of log K vs ? were obtained in the solvents acetone-d6, CD3CN, and CD3NO2 with ρ = 0.28-0.36.These results are interpreted in terms of the dominance of the endo anomeric effect involving overlap of the endocyclic N(3) and O(1) p lone pairs with the axial P-N ?* orbital (p-XC6H4NHP).

Phosphorotriamides as urease inhibitors

Certain phosphorotriamides of the formula STR1 wherein R is hydrogen, phenyl, 4-nitrophenyl, 4-aminophenyl, 4-cyanophenyl or 3-trifluromethylphenyl are useful as inhibitors of the enzyme urease.